Literature DB >> 7888935

Drug treatment of Parkinson's disease.

N Quinn1.   

Abstract

A wide variety of drugs is available for treating Parkinson's disease, including anticholinergics, amantadine levodopa, dopamine agonists, and selegiline. In younger patients (less than 50) levodopa is usually delayed provided that adequate relief of symptoms can be achieved with other drugs. In older patients (greater than 70) levodopa should be started as soon as symptom relief is required. Between these ages there is no consensus, but at present most such patients should probably be given controlled release levodopa before a dopamine agonist is added. Fluctuations can often be alleviated by giving controlled release preparations of levodopa, by giving small doses at frequent intervals, by adding selegiline or a long acting oral agonist, or by subcutaneous apomorphine. Dyskinesia can be peak dose, diphasic, or "off period." The diphasic form is hardest to alleviate. Psychiatric side effects should initially be managed by changing the antiparkinsonian treatment before resorting to antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7888935      PMCID: PMC2548944          DOI: 10.1136/bmj.310.6979.575

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  23 in total

1.  Mood swings associated with the 'on-off' phenomenon in Parkinson's disease.

Authors:  H Nissenbaum; N P Quinn; R G Brown; B Toone; A M Gotham; C D Marsden
Journal:  Psychol Med       Date:  1987-11       Impact factor: 7.723

2.  Protein redistribution diet restores motor function in patients with dopa-resistant "off" periods.

Authors:  J H Pincus; K Barry
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

3.  Dystonia in Parkinson's disease: clinical and pharmacological features.

Authors:  W H Poewe; A J Lees; G M Stern
Journal:  Ann Neurol       Date:  1988-01       Impact factor: 10.422

4.  The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.

Authors:  J G Nutt; W R Woodward; J P Hammerstad; J H Carter; J L Anderson
Journal:  N Engl J Med       Date:  1984-02-23       Impact factor: 91.245

5.  "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

Authors:  C D Marsden; J D Parkes
Journal:  Lancet       Date:  1976-02-07       Impact factor: 79.321

6.  Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa.

Authors:  F Lhermitte; Y Agid; J L Signoret
Journal:  Arch Neurol       Date:  1978-05

7.  Cholinergic-dependent cognitive deficits in Parkinson's disease.

Authors:  B Dubois; F Danzé; B Pillon; G Cusimano; F Lhermitte; Y Agid
Journal:  Ann Neurol       Date:  1987-07       Impact factor: 10.422

8.  Young onset Parkinson's disease.

Authors:  N Quinn; P Critchley; C D Marsden
Journal:  Mov Disord       Date:  1987       Impact factor: 10.338

9.  The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.

Authors:  M A Hely; J G Morris; D Rail; W G Reid; D J O'Sullivan; P M Williamson; S Genge; G A Broe
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-03       Impact factor: 10.154

10.  Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

Authors:  U K Rinne
Journal:  Neurology       Date:  1987-05       Impact factor: 9.910

View more
  19 in total

Review 1.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 2.  The role of plant-derived drugs and herbal medicines in healthcare.

Authors:  P A De Smet
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 3.  Parkinson's disease.

Authors:  J R Playfer
Journal:  Postgrad Med J       Date:  1997-05       Impact factor: 2.401

4.  Diagnosis and treatment of Parkinson's disease. Anticholinergic drugs are not contraindicated after iridotomy.

Authors:  A Fink
Journal:  BMJ       Date:  1995-06-24

5.  Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance.

Authors:  Dominik Stämpfli; Stefan Weiler; Andrea M Burden
Journal:  Eur Child Adolesc Psychiatry       Date:  2020-07-03       Impact factor: 4.785

Review 6.  Treating and preventing levodopa-induced dyskinesias: current and future strategies.

Authors:  F Durif
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

Review 7.  Gene therapy: a viable therapeutic strategy for Parkinson's disease?

Authors:  Alexander L Berry; Thomas Foltynie
Journal:  J Neurol       Date:  2010-10-21       Impact factor: 4.849

8.  Decrease of antiparkinsonian drugs before start of an antipsychotic in patients on levodopa treatment?

Authors:  David A M C van de Vijver; Raymund A C Roos; Paul A F Jansen; Arijan J Porsius; Anthonius de Boer
Journal:  Pharm World Sci       Date:  2004-10

9.  Sonic Hedgehog Protein : A Novel Approach to the Treatment of Neurodegenerative Disorders?

Authors:  K Pang; T D Ingolia
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

10.  Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease.

Authors:  N V Fedorova; I P Chigir'
Journal:  Neurosci Behav Physiol       Date:  2007-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.